ChickenStockChickenStock

AI English summary of an SEC filing — figures as filed

Thermo Fisher Scientific logoThermo Fisher Scientific TMO

The company said revenue for Q3 2026 rose 9% to $12.14 billion from $11.12 billion a year earlier, and organic revenue growth was 6%.

8-KResults of Operations and Financial ConditionFiled Period of report Summary published (UTC)

Key points

AI summary
  1. The company said revenue for Q3 2026 rose 9% to $12.14 billion from $11.12 billion a year earlier, and organic revenue growth was 6%.

  2. Thermo Fisher said GAAP diluted EPS for Q3 rose 9% to $4.64, adjusted EPS rose 15% to $6.68, and GAAP operating margin was 18.6%, compared with 17.4% a year earlier.

  3. The company said adjusted operating income for Q3 was $2.97 billion, 15% higher than a year earlier, and adjusted operating margin was 24.5%, compared with 23.3% a year earlier.

  4. Thermo Fisher reported that net cash provided by operating activities for the 9 months ended 2026 was $5,867 million, and free cash flow (non-GAAP) was $4,618 million, compared with $3,319 million a year earlier.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Q3 Revenue $12.14 billion, Organic Growth 6%

The company said revenue for Q3 2026 rose 9% to $12.14 billion from $11.12 billion a year earlier, and organic revenue growth was 6%.

Source · Based on the filing body and exhibits

Q3 GAAP and Adjusted Earnings Metrics

Thermo Fisher said GAAP diluted EPS for Q3 rose 9% to $4.64, adjusted EPS rose 15% to $6.68, and GAAP operating margin was 18.6%, compared with 17.4% a year earlier.

Source · Based on the filing body and exhibits

Q3 Adjusted Operating Income and Margin

The company said adjusted operating income for Q3 was $2.97 billion, 15% higher than a year earlier, and adjusted operating margin was 24.5%, compared with 23.3% a year earlier.

Source · Based on the filing body and exhibits

9-Month Operating Cash Flow and Free Cash Flow

Thermo Fisher reported that net cash provided by operating activities for the 9 months ended 2026 was $5,867 million, and free cash flow (non-GAAP) was $4,618 million, compared with $3,319 million a year earlier.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.